metamorworks / Shutterstock.com
24 June 2021Big PharmaMuireann Bolger
SPCs outlive patent protections in 91% of cases, new report reveals
Supplementary protection certificates (SPCs) outlive medicinal patents in more than nine in ten cases, a new report has found.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Generics
10 July 2020 The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Editor's picks
Editor's picks
Generics
10 July 2020 The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Generics
10 July 2020 The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.